Cargando…

Serological response to a single dose of a SARS-CoV-2 mRNA vaccine

The delays in the production and delivery of COVID-19 vaccines and the growing number of fatal infections across the globe raised the question whether it would be more advantageous to vaccinate a larger group of individuals with one dose instead of a smaller one with two doses. Through a group of va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos, Angélica, Cardoso, Maria João, Norton, Pedro, Sarmento, António, Guimarães, João Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252705/ https://www.ncbi.nlm.nih.gov/pubmed/34224753 http://dx.doi.org/10.1016/j.jviromet.2021.114223

Ejemplares similares

Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers
por: Ramos, Angélica, et al.
Publicado: (2022)

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines
por: Narasimhan, Madhusudhanan, et al.
Publicado: (2021)

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
por: Cucunawangsih, Cucunawangsih, et al.
Publicado: (2022)

Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history
por: Ota, Kenji, et al.
Publicado: (2023)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients
por: Hoffman, T.W., et al.
Publicado: (2022)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients
por: Pascale, Sara Pasquina, et al.
Publicado: (2022)

An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines
por: Iglesias García, Graciela, et al.
Publicado: (2022)

Myocarditis following mRNA vaccination against SARS-CoV-2, a case series
por: King, William W., et al.
Publicado: (2021)

Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2
por: Lee, Kuo-Ming, et al.
Publicado: (2023)

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
por: Casado, José L., et al.
Publicado: (2022)

Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine
por: Silva Vasconcelos, Germana, et al.
Publicado: (2023)

Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine
por: Marcelino, João, et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence in healthcare workers: The experience of a Portuguese COVID-19 front-line hospital during the 1st pandemic wave
por: Ramos, Angelica, et al.
Publicado: (2022)

Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose
por: Margioris, Andrew N.
Publicado: (2022)

SARS‐CoV‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID‐19 vaccination
por: Castruita, Jose Alfredo Samaniego, et al.
Publicado: (2023)

The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
por: Tolan, Nicole V., et al.
Publicado: (2022)

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Bradley, Todd, et al.
Publicado: (2021)

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine
por: Belda, Francisco, et al.
Publicado: (2022)

Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report
por: SOUAID, Karim, et al.
Publicado: (2021)

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection
por: Psaridi, Loukia, et al.
Publicado: (2022)

Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults
por: Simone, Anthony, et al.
Publicado: (2022)

Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
por: Anastasi, Emanuela, et al.
Publicado: (2022)

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost
por: Kim, Woo Joo, et al.
Publicado: (2023)

Tu1268: LONGITUDINAL ASSESSMENT OF SEROLOGICAL RESPONSE AFTER THREE DOSES OF SARS-COV-2 MRNA VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Gandle, Cassandra, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
por: Gressens, Simon B., et al.
Publicado: (2023)

New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster
por: Arismendez, Alan A., et al.
Publicado: (2023)

Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2
por: Kageyama, Takahiro, et al.
Publicado: (2022)

Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population
por: Genç Bahçe, Yasemin, et al.
Publicado: (2023)

A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection
por: Laranjeira, Paula, et al.
Publicado: (2022)

Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Serological Response to BNT162b2 Anti-Sars-Cov-2 mRNA Vaccine in Patients with Transfusion Dependent Thalassemia
por: Zucano, Stefania, et al.
Publicado: (2021)

Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old
por: Tomaiuolo, Rossella, et al.
Publicado: (2022)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
por: Mohamed, Sara, et al.
Publicado: (2023)

An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines
por: Al-Sheboul, Suhaila A., et al.
Publicado: (2022)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Krammer, Florian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0g2ksdorpoo3lqn8p5lsnkdbuj